CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia - Wikidata - awgldk - TriplyDB

CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia

CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia

http://www.wikidata.org/entity/Q37098861

about

Cord Blood as a Source of Natural Killer Cells Selection and expansion of natural killer cells for NK cell-based immunotherapy Direct and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney Transplantation Functional Reconstitution of Natural Killer Cells in Allogeneic Hematopoietic Stem Cell Transplantation Correlation and Agreement of Handheld Spirometry with Laboratory Spirometry in Allogeneic Hematopoietic Cell Transplant Recipients Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches.Notch signaling at later stages of NK cell development enhances KIR expression and functional maturation Reduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic review Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera.CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire Adaptive Natural Killer Cell and Killer Cell Immunoglobulin-Like Receptor-Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell Tr Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function.CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT.Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy Cytomegalovirus induces strong antileukemic effect in acute myeloid leukemia patients following sibling HSCT without ATG-containing regimen.Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells.Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study.Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission.Tumor control by human cytomegalovirus in a murine model of hepatocellular carcinoma Alloreactivity of virus-specific T cells: possible implication of graft-versus-host disease and graft-versus-leukemia effects.Human Cytomegalovirus Infection Enhances NK Cell Activity In Vitro.Prognostic impact of viral reactivations in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation in first complete response.The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT).At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias.Natural killer cells and regulatory T cells: how to manipulate a graft for optimal GVL.Hunting for clinical translation with innate-like immune cells and their receptors.The role of dendritic cells in graft-versus-tumor effect Clinical utility of natural killer cells in cancer therapy and transplantation.Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation.Cancer Immunotherapy Using γδT Cells: Dealing with Diversity.The role of hematopoietic stem cell transplantation in chronic myeloid leukemia.The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer.Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation.NK cell-based cancer immunotherapy: from basic biology to clinical application.Expanding role of cytomegalovirus as a human pathogen.Cytomegalovirus and immunotherapy: opportunistic pathogen, novel target for cancer and a promising vaccine vector.

P2860

Q26771337-D119B0BE-2B15-4FB3-9354-C6DF570549DA Q26774777-F498E202-04D1-4019-B843-263A59254704 Q26863724-DFD946D1-BCC0-47CC-A13C-95A799D4DA2C Q28069682-6FBBE1EB-105A-4C1D-922A-A7B36C56E45D Q28391717-8253674F-7D49-4C30-9CF8-474DFB8D7B1F Q33429827-C4A45F2D-6EBC-4FDF-A105-4DB4B7196A35 Q33645271-9D117C72-9970-484B-9A4B-E88236AB465D Q33734872-8EF864B4-0E63-443F-B23D-093B056A3D4D Q34218967-CA209511-B9C6-45B7-82C2-AFA43EE8C521 Q34770016-B60DFEAD-CE29-4DA9-B62C-5A06BA97A0B5 Q35726245-E06D5D18-DEB2-4CAE-9BAF-CF72EFDD2087 Q35757381-F649962E-EE1D-4D0B-8E95-965B52B35550 Q36020519-612DB7D8-063A-47E5-9F42-308CF02343AB Q36181155-4631F1BA-F653-4733-85D8-60C9184E6628 Q36540532-A8E7DCC9-58A2-4550-AAD2-914C34CEB6E1 Q36723108-7E1FD6A4-6EB6-4403-A8F8-16145F8F6CC5 Q36779768-C7EA7907-B8B3-4AB7-A192-0F23975F2877 Q36841211-7AF958C2-344F-4A96-A951-BF97FC770082 Q36920445-0F5F9519-5F62-4C33-B17A-9DFCF8ACD905 Q36966726-83FF5D9D-C9E9-4326-B151-939C6CC21E04 Q37022512-96CB562D-C72D-4BD8-B6CC-DA73355E8CA6 Q37086251-ACB317BE-4DC5-4DAF-A5D1-11BFCB9FF07C Q37225207-02C1858F-E43A-4249-A230-9F0B2373BD4E Q37229016-9BBFED46-9CFD-4B74-979E-29034C7C1E66 Q37381119-A27A5FCB-1ADB-4278-9699-C9A8BDCE2D4C Q37467919-ABAA540D-1682-4A96-AE29-DB1921526A42 Q37589671-DE104EB8-19F7-4574-98C2-F9D70BC7FDF6 Q38151057-58ACF567-A603-492A-B9C5-12B5F5BC62DD Q38169654-A5043F20-1C3F-400A-9376-E321354CFD6E Q38171917-692C58A9-65EF-490B-BCE9-A31464035888 Q38193807-53832BBC-FF3C-4A0C-A410-549CC7AFE23B Q38195120-7D4DD186-6E18-4CDF-BF0F-2BDE1AA96D42 Q38281851-6BF0492B-1600-4F68-B4BD-FD2C9C5BF432 Q38283536-1FABDBB7-C595-4F1C-BC2F-E3817EF2F879 Q38392690-36FB067F-164B-48F1-B752-4788876A89E0 Q38513534-AE3AF4CA-3BEC-4CF2-9674-60CB95BD45EB Q38617612-D711C30C-6C71-4C46-9F84-93603BE03171 Q38640489-0A379096-BD15-4D99-8C7A-2D24901DABD8 Q38673038-4CF7A3E4-FDD9-4589-915B-35883FD05664 Q38703382-947888AC-AFFF-462D-805D-C554E14F9165

P2860

CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia

http://www.wikidata.org/entity/Q37098861

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

CMV reactivation after allogen ...... tion in acute myeloid leukemia

@en

CMV reactivation after allogen ...... ion in acute myeloid leukemia.

@nl

type

label

CMV reactivation after allogen ...... tion in acute myeloid leukemia

@en

CMV reactivation after allogen ...... ion in acute myeloid leukemia.

@nl

prefLabel

CMV reactivation after allogen ...... tion in acute myeloid leukemia

@en

CMV reactivation after allogen ...... ion in acute myeloid leukemia.

@nl

P1433

Q37098861-A6F4C3E9-7DB5-413D-9913-353EEF23825E

P1476

Q37098861-C8AE277D-3902-4772-B6F0-811F7D448524

P2093

Q37098861-18E7E82A-41C1-4E4F-AF7C-318FB0AB5F4D

Q37098861-749D9E2E-3C48-4D3D-97AC-D3483C03AD0C

Q37098861-9C3B59FF-2759-4CDD-875E-41083B683F41

Q37098861-F8888FF6-39FA-4A8D-88E8-7AE55EFBB7D5

Q37098861-FFFE563F-05DF-487C-8CDF-AAA70C76D193

P2860

Q37098861-04F463DA-2196-4DD3-9DEB-F1169BFAEE1C

Q37098861-17A0DDDE-543C-4F3B-B616-B43DDBF708E6

Q37098861-1C69BF63-D26E-49B0-92CF-FCABB810C0B5

Q37098861-2C220AE3-32B1-4485-86EE-DAF8208556E9

Q37098861-2DFB56A8-B4C3-4A85-A89C-5FA792577CF5

Q37098861-57FA79AF-E45F-4150-921A-361F885D05C6

Q37098861-651C8BBF-B494-49AA-BFDF-60A6E6CCA1D9

Q37098861-6641EC0B-567E-48A0-AECD-EE954F1CC9D6

Q37098861-6FF0DC66-0724-4F83-B112-54B4225502D4

Q37098861-7D541CA0-ED5B-4627-86AD-2D54593A4911

P304

Q37098861-DCEF03EA-5678-461D-BFEC-3483412DA0A7

P31

Q37098861-051BA54B-CD6D-4236-B9D6-0354125091DB

P356

Q37098861-E2410F26-9300-44E3-B26C-9D9E7A139BF3

P407

Q37098861-935B9CF2-0DC9-4CE1-B71F-1A869A8BEDF2

P433

Q37098861-76038A92-E34D-45C8-9634-0F9B7ECD6EAB

P478

Q37098861-65F869CB-8221-4BC0-89A4-BA984F583298

P50

Q37098861-1D4B1C77-3E4F-498B-879E-6DCD0D8F2823

Q37098861-BDFA2C3E-F526-4EAF-8660-12F52F0CB9D2

Q37098861-FA7F3DF4-9682-425E-A3C0-90335EF892B3

P577

Q37098861-E59F04C4-3104-43CF-8E04-07AC9F9243E8

P5875

Q37098861-B0CE7889-8798-4554-B275-7E4288056675

P698

Q37098861-A45CEC85-7EA9-41BE-A76B-0256EB2D4621

P921

Q37098861-99F54C99-75B7-4E23-BF04-8E010C0EC977

P932

Q37098861-7CB87EEE-1C18-42B0-B5DA-A0B9321D9060

P356

BLOOD-2013-02-487074

P1433

P1476

CMV reactivation after allogen ...... tion in acute myeloid leukemia

@en

P2093

Hu Xie

http://www.w3.org/2001/XMLSchema#string

Margaret L Green

http://www.w3.org/2001/XMLSchema#string

Roland B Walter

http://www.w3.org/2001/XMLSchema#string

Stanley R Riddell

http://www.w3.org/2001/XMLSchema#string

Wendy M Leisenring

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy.

Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function.

Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.

CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML.

Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.

1994 Consensus Conference on Acute GVHD Grading

NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs.

The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.

Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts.

P304

1316-1324

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-02-487074

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Brenda M Sandmaier

Marco Mielcarek

P577

2013-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

237070822

http://www.w3.org/2001/XMLSchema#string

P698

23744585

http://www.w3.org/2001/XMLSchema#string

P921

P932

3744995

http://www.w3.org/2001/XMLSchema#string